Perceptive Advisors - Q2 2024 holdings

$4.15 Billion is the total value of Perceptive Advisors's 110 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 41.1% .

 Value Shares↓ Weighting
CERE  CEREVEL THERAPEUTICS HLDNG I$441,402,480
-3.3%
10,794,8760.0%10.63%
+33.2%
FOLD  AMICUS THERAPEUTICS INC$278,329,964
-15.8%
28,057,4560.0%6.70%
+15.9%
SellARCELLX INC$214,674,695
-21.5%
3,889,739
-1.1%
5.17%
+8.0%
IOVA BuyIOVANCE BIOTHERAPEUTICS INC$207,983,798
-27.2%
25,933,142
+34.6%
5.01%
+0.3%
SellNUVALENT INC$193,372,981
-7.5%
2,549,077
-8.4%
4.66%
+27.4%
RYTM BuyRHYTHM PHARMACEUTICALS INC$141,516,534
-0.1%
3,446,579
+5.4%
3.41%
+37.6%
PCVX SellVAXCYTE INC$140,645,530
+6.5%
1,862,608
-3.6%
3.39%
+46.7%
BuySOLENO THERAPEUTICS INC$130,763,021
-0.6%
3,204,976
+4.2%
3.15%
+36.8%
ITCI BuyINTRA-CELLULAR THERAPIES INC$117,556,715
+61.0%
1,716,407
+62.6%
2.83%
+121.5%
IMTX BuyIMMATICS N.V$93,961,168
+95.1%
8,086,159
+76.5%
2.26%
+168.4%
NBIX SellNEUROCRINE BIOSCIENCES INC$89,472,972
-19.4%
649,909
-19.2%
2.16%
+11.0%
BuyAPOGEE THERAPEUTICS INC$82,856,776
-39.5%
2,105,636
+2.2%
2.00%
-16.7%
MDGL SellMADRIGAL PHARMACEUTICALS INC$74,130,336
-35.4%
264,600
-38.5%
1.79%
-11.1%
CRY BuyARTIVION INC$71,658,482
+26.9%
2,793,703
+4.7%
1.73%
+74.7%
BuySPYRE THERAPEUTICS INC$71,259,233
-26.5%
3,031,018
+18.6%
1.72%
+1.1%
CRNX  CRINETICS PHARMACEUTICALS IN$66,119,132
-4.3%
1,476,2030.0%1.59%
+31.8%
EOLS  EVOLUS INC$62,428,708
-22.5%
5,753,7980.0%1.50%
+6.7%
SWTX SellSPRINGWORKS THERAPEUTICS INC$62,267,079
-44.1%
1,652,962
-26.9%
1.50%
-23.0%
BuyCARGO THERAPEUTICS INC$60,474,925
-21.4%
3,683,004
+6.8%
1.46%
+8.2%
 ASTRIA THERAPEUTICS INC$59,017,322
-35.3%
6,485,4200.0%1.42%
-11.0%
NTRA SellNATERA INC$57,393,700
-17.1%
530,000
-30.0%
1.38%
+14.0%
VRCA  VERRICA PHARMACEUTICALS INC$51,753,037
+23.1%
7,099,1820.0%1.25%
+69.7%
SellBIOHAVEN LTD$51,552,403
-45.4%
1,485,232
-13.9%
1.24%
-24.8%
IMVT SellIMMUNOVANT INC$50,787,950
-47.0%
1,923,786
-35.1%
1.22%
-27.0%
MGTX  MEIRAGTX HLDGS PLC$47,667,625
-30.6%
11,331,1030.0%1.15%
-4.5%
PTGX BuyPROTAGONIST THERAPEUTICS INC$43,961,668
+52.8%
1,268,735
+27.6%
1.06%
+110.5%
 SOLID BIOSCIENCES INC$39,160,682
-57.4%
6,906,6460.0%0.94%
-41.4%
CELC  CELCUITY INC$38,694,130
-24.2%
2,362,2790.0%0.93%
+4.4%
MDT SellMEDTRONIC PLC$38,620,242
-69.0%
490,665
-65.7%
0.93%
-57.3%
VKTX SellVIKING THERAPEUTICS INC$38,240,195
-53.1%
721,377
-27.4%
0.92%
-35.4%
APLT  APPLIED THERAPEUTICS INC$37,383,350
-31.3%
8,005,0000.0%0.90%
-5.5%
AXSM SellAXSOME THERAPEUTICS INC$36,958,436
-58.1%
459,111
-58.5%
0.89%
-42.3%
CNTA BuyCENTESSA PHARMACEUTICALS PLCsponsored ads$35,517,762
+1.9%
3,933,307
+27.6%
0.86%
+40.2%
TARS  TARSUS PHARMACEUTICALS INC$35,236,587
-25.2%
1,296,4160.0%0.85%
+2.9%
AKRO BuyAKERO THERAPEUTICS INC$35,187,584
+0.4%
1,499,897
+8.1%
0.85%
+38.3%
VRNA SellVERONA PHARMA PLCsponsored ads$35,191,664
-41.9%
2,433,725
-35.3%
0.85%
-19.9%
EWTX SellEDGEWISE THERAPEUTICS INC$33,434,070
-21.0%
1,856,417
-20.0%
0.80%
+8.8%
BuyACRIVON THERAPEUTICS INC$31,092,976
+44.6%
5,360,858
+78.2%
0.75%
+99.2%
SellPRAXIS PRECISION MEDICINES I$31,029,513
-38.1%
750,230
-8.7%
0.75%
-14.8%
ADMA SellADMA BIOLOGICS INC$30,979,780
-27.0%
2,771,000
-56.9%
0.75%
+0.4%
BBIO SellBRIDGEBIO PHARMA INC$30,784,714
-29.5%
1,215,346
-13.9%
0.74%
-3.0%
ALDX BuyALDEYRA THERAPEUTICS INC$30,703,067
+9.3%
9,275,851
+7.9%
0.74%
+50.4%
NAUT  NAUTILUS BIOTECHNOLOGY INC$29,470,453
-20.4%
12,594,2110.0%0.71%
+9.6%
NewCONTINEUM THERAPEUTICS INCcl a$27,589,0231,566,668
+100.0%
0.66%
ISRG SellINTUITIVE SURGICAL INC$27,491,730
-32.3%
61,800
-39.3%
0.66%
-6.9%
ARVN SellARVINAS INC$27,358,678
-46.4%
1,027,749
-16.9%
0.66%
-26.2%
RCKT SellROCKET PHARMACEUTICALS INC$26,839,233
-44.7%
1,246,597
-30.8%
0.65%
-23.9%
SellDISC MEDICINE INC$24,943,406
-57.4%
553,437
-41.1%
0.60%
-41.3%
LIVN BuyLIVANOVA PLC$24,340,080
+45.5%
444,000
+48.5%
0.59%
+100.0%
SellCG ONCOLOGY INC$23,162,751
-59.5%
733,695
-43.7%
0.56%
-44.3%
XENE SellXENON PHARMACEUTICALS INC$22,741,151
-40.8%
583,256
-34.6%
0.55%
-18.5%
OCUL  OCULAR THERAPEUTIX INC$22,739,361
-24.8%
3,324,4680.0%0.55%
+3.6%
 PEPGEN INC$22,510,590
+8.6%
1,410,4380.0%0.54%
+49.3%
VRDN SellVIRIDIAN THERAPEUTICS INC$21,230,082
-66.8%
1,631,828
-55.4%
0.51%
-54.4%
 ORCHESTRA BIOMED HLDGS INC$20,748,930
+54.6%
2,545,8810.0%0.50%
+112.8%
MRUS NewMERUS N V$17,751,000300,000
+100.0%
0.43%
NewRAPPORT THERAPEUTICS INC$17,402,737748,183
+100.0%
0.42%
BuyTYRA BIOSCIENCES INC$16,107,798
+46.8%
1,007,367
+50.5%
0.39%
+102.1%
NewINHIBRX BIOSCIENCES INC$15,077,2481,064,026
+100.0%
0.36%
ARQT BuyARCUTIS BIOTHERAPEUTICS INC$14,494,050
+95.0%
1,558,500
+107.8%
0.35%
+168.5%
ATHA  ATHIRA PHARMA INC$14,317,855
-3.3%
5,402,9640.0%0.34%
+33.2%
BuyZYMEWORKS INC$14,192,221
+25.5%
1,667,711
+55.2%
0.34%
+72.7%
CGEM NewCULLINAN THERAPEUTICS INC$13,078,535749,916
+100.0%
0.32%
 PROCEPT BIOROBOTICS CORP$12,869,158
+23.6%
210,6590.0%0.31%
+70.3%
INSM NewINSMED INC$12,060,000180,000
+100.0%
0.29%
BCYC NewBICYCLE THERAPEUTICS PLCsponsored ads$11,577,280572,000
+100.0%
0.28%
ICLR NewICON PLC$9,795,93831,250
+100.0%
0.24%
NewTEMPUS AI INCcl a$9,625,000275,000
+100.0%
0.23%
 ARRIVENT BIOPHARMA INC$7,698,250
+3.9%
415,0000.0%0.18%
+42.3%
SellENGENE HOLDINGS INC$7,544,000
-55.4%
800,000
-19.9%
0.18%
-38.5%
SBTX  ARS PHARMACEUTICALS INC$7,380,885
-16.7%
867,3190.0%0.18%
+14.8%
ARGX NewARGENX SEsponsored adr$6,708,62415,600
+100.0%
0.16%
ALLO NewALLOGENE THERAPEUTICS INC$6,349,2502,725,000
+100.0%
0.15%
VERU BuyVERU INC$5,942,335
+52.0%
7,063,277
+26.5%
0.14%
+110.3%
KALV  KALVISTA PHARMACEUTICALS INC$5,890,000
-0.7%
500,0000.0%0.14%
+36.5%
RXRX NewRECURSION PHARMACEUTICALS INcl a$5,769,225769,230
+100.0%
0.14%
EYPT BuyEYEPOINT PHARMACEUTICALS INC$5,570,384
-54.3%
640,274
+8.6%
0.13%
-37.1%
IMVT BuyIMMUNOVANT INCcall$5,280,000
+63.4%
200,000
+100.0%
0.13%
+122.8%
 HELIX ACQUISITION CORP II$5,110,000
-1.7%
500,0000.0%0.12%
+35.2%
MREO NewMEREO BIOPHARMA GROUP PLCspon ads$4,511,7001,253,250
+100.0%
0.11%
CABA SellCABALETTA BIO INC$4,376,137
-85.1%
585,045
-65.9%
0.10%
-79.5%
SellPRECISION BIOSCIENCES INC$4,147,831
-36.3%
426,293
-11.3%
0.10%
-12.3%
NewSKYE BIOSCIENCE INC$4,005,000500,000
+100.0%
0.10%
 TRINITY BIOTECH PLCspons ard new$3,834,000
+4.4%
1,800,0000.0%0.09%
+43.8%
IRTC SellIRHYTHM TECHNOLOGIES INC$3,789,466
-86.7%
35,205
-85.6%
0.09%
-81.7%
LYRA  LYRA THERAPEUTICS INC$3,533,844
-95.5%
12,757,5620.0%0.08%
-93.9%
BDSX NewBIODESIX INC$3,326,0362,173,880
+100.0%
0.08%
 ENVVENO MEDICAL CORPORATION$3,272,404
-3.5%
623,3150.0%0.08%
+33.9%
FHTX NewFOGHORN THERAPEUTICS INC$3,128,000544,000
+100.0%
0.08%
NBTX  NANOBIOTIXsponsored ads$2,775,330
-23.1%
555,0660.0%0.07%
+6.3%
SAVA NewCASSAVA SCIENCES INCput$2,260,050183,000
+100.0%
0.05%
 ABSCI CORPORATION$2,156,000
-45.8%
700,0000.0%0.05%
-25.7%
XBI NewSPDR SER TRs&p biotech$2,101,27222,665
+100.0%
0.05%
XFOR  X4 PHARMACEUTICALS INC$2,056,363
-58.3%
3,545,4540.0%0.05%
-41.9%
FBRX  FORTE BIOSCIENCES INC$1,753,498
-22.9%
3,265,3590.0%0.04%
+5.0%
RVNC  REVANCE THERAPEUTICS INC$1,542,000
-47.8%
600,0000.0%0.04%
-28.8%
NewSTRUCTURE THERAPEUTICS INCsponsored ads$1,368,63834,852
+100.0%
0.03%
NVAX SellNOVAVAX INCput$1,266,000
-62.2%
100,000
-85.7%
0.03%
-49.2%
 KYVERNA THERAPEUTICS INC$1,125,000
-69.8%
150,0000.0%0.03%
-58.5%
FATE NewFATE THERAPEUTICS INC$1,133,486345,575
+100.0%
0.03%
EGRX NewEAGLE PHARMACEUTICALS INC$970,844173,365
+100.0%
0.02%
 VBI VACCINES INC CDA$832,728
+10.0%
1,261,7100.0%0.02%
+53.8%
TCMD SellTACTILE SYS TECHNOLOGY INC$747,910
-94.9%
62,639
-93.1%
0.02%
-93.0%
 SYROS PHARMACEUTICALS INC$602,451
-3.6%
116,7540.0%0.02%
+36.4%
NewSINGULAR GENOMICS SYSTEMS IN$599,07170,896
+100.0%
0.01%
 CAREMAX INCcl a new$342,174
-42.1%
122,6430.0%0.01%
-20.0%
AXGN SellAXOGEN INC$220,248
-98.2%
30,421
-98.0%
0.01%
-97.7%
 REVOLUTION MEDICINES INC*w exp 12/17/202$25,525
-44.1%
250,0000.0%0.00%0.0%
CMAXW  CAREMAX INC*w exp 06/08/202$846
-17.5%
60,0000.0%0.00%
 SURROZEN INC*w exp 08/01/203$2,767
-45.0%
166,6660.0%0.00%
ExitAMYLYX PHARMACEUTICALS INC$0-300,000
-100.0%
-0.02%
KURA ExitKURA ONCOLOGY INC$0-48,200
-100.0%
-0.02%
OMIC ExitSINGULAR GENOMICS SYSTEMS IN$0-2,126,893
-100.0%
-0.02%
AGIO ExitAGIOS PHARMACEUTICALS INCcall$0-100,000
-100.0%
-0.05%
APLT ExitAPPLIED THERAPEUTICS INCcall$0-500,000
-100.0%
-0.06%
ExitNEWAMSTERDAM PHARMA COMPANYordinary shares$0-175,000
-100.0%
-0.07%
ESTA ExitESTABLISHMENT LABS HLDGS INC$0-82,299
-100.0%
-0.07%
ExitAMYLYX PHARMACEUTICALS INCcall$0-1,679,125
-100.0%
-0.08%
XBI ExitSPDR SER TRput$0-50,000
-100.0%
-0.08%
MGNX ExitMACROGENICS INC$0-378,327
-100.0%
-0.10%
IBRX ExitIMMUNITYBIO INC$0-1,052,887
-100.0%
-0.10%
COGT ExitCOGENT BIOSCIENCES INC$0-883,333
-100.0%
-0.10%
MORF ExitMORPHIC HLDG INC$0-288,221
-100.0%
-0.18%
RAPT ExitRAPT THERAPEUTICS INC$0-1,223,472
-100.0%
-0.19%
ExitMOONLAKE IMMUNOTHERAPEUTICSclass a ord$0-339,012
-100.0%
-0.30%
ExitDISC MEDICINE INCput$0-300,000
-100.0%
-0.33%
ABBV ExitABBVIE INC$0-106,500
-100.0%
-0.34%
RVMD ExitREVOLUTION MEDICINES INC$0-618,885
-100.0%
-0.35%
AUTL ExitAUTOLUS THERAPEUTICS PLCspon ads$0-4,330,745
-100.0%
-0.48%
TMCI ExitTREACE MED CONCEPTS INC$0-2,304,954
-100.0%
-0.53%
ExitLANDOS BIOPHARMA INC$0-1,486,991
-100.0%
-0.56%
SRPT ExitSAREPTA THERAPEUTICS INC$0-525,683
-100.0%
-1.19%
FUSN ExitFUSION PHARMACEUTICALS INC$0-6,825,395
-100.0%
-2.55%
INBX ExitINHIBRX INC$0-4,256,104
-100.0%
-2.60%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2024-08-16
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES45Q2 202415.7%
AMICUS THERAPEUTICS SHARES42Q2 202414.0%
ALDEYRA THERAPEUTICS SHARES38Q2 20243.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
ADMA BIOLOGICS SHARES32Q2 20241.4%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
IOVANCE BIOTHERAPEUTICS INC29Q2 20249.1%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q2 2024 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
BIODESIX INCMay 13, 20246,673,8805.6%
TRINITY BIOTECH PLCMay 01, 202456,000,00026.8%
RHYTHM PHARMACEUTICALS, INC.April 17, 20245,143,5758.3%
VBI Vaccines Inc/BCApril 17, 20241,261,7104.4%
Acrivon Therapeutics, Inc.April 15, 20245,360,85817.4%
Contineum Therapeutics, Inc.April 15, 20241,566,6698.5%
Landos Biopharma, Inc.April 10, 20241,486,99147.7%
PRECISION BIOSCIENCES INCMarch 14, 2024500,0007.9%
ARTIVION, INC.March 11, 20242,383,9785.8%
RELMADA THERAPEUTICS, INC.Sold outMarch 06, 202400.0%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-10-31
SC 13G2024-10-29
SC 13G2024-10-25
SC 13G2024-10-22
SC 13D/A2024-10-17
SC 13G2024-10-16
SC 13G2024-10-10
SC 13G2024-09-27
SC 13D/A2024-09-24
SC 13G2024-09-23

View Perceptive Advisors's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export Perceptive Advisors's holdings